| 双歧杆菌在胃癌FOLFOX6方案化疗中的作用研究 |
| |
| 引用本文： | 郭楠楠,武宜婷,赵峰,刘燕文.双歧杆菌在胃癌FOLFOX6方案化疗中的作用研究[J].蚌埠医学院学报,2021,46(11):1510-1512, 1516. |
| |
| 作者姓名： | 郭楠楠 武宜婷 赵峰 刘燕文 |
| |
| 作者单位： | 东南大学附属中大医院江北院区 肿瘤内科, 江苏 南京 210048 |
| |
| 基金项目： | 国家自然基金资助项目81773284 |
| |
| 摘 要： | 目的研究双歧杆菌在胃癌FOLFOX6方案化疗中的作用。方法选择80例胃癌病人作为研究对象，按随机数字表法分为观察组和对照组，对照组给予FOLFOX6方案化疗，观察组在对照组的基础上给予双歧杆菌治疗。比较2组的淋巴细胞总数（TLC）、白细胞计数（WBC）、中性粒细胞（N），肠道菌群，胃肠道症状分级评分量表（GSRS），临床疗效以及不良反应。结果2组病人化疗后TLC、WBC和N均较化疗前有不同程度上升（P < 0.05）；对照组化疗后TLC、N均明显低于观察组（P < 0.01），2组化疗后WBC差异无统计学意义（P>0.05）。化疗后对照组乳酸杆菌低于观察组（P < 0.01），肠杆菌、肠球菌、GSRS均高于观察组（P < 0.05~P < 0.01）。2组总缓解率差异无统计学意义（P>0.05）。观察组不良反应发生率低于对照组（P < 0.05）。结论双歧杆菌可提高机体免疫力，改善胃肠道菌群分布及症状，从而降低FOLFOX6方案化疗的不良反应。
|
| 关 键 词： | 胃肿瘤 双歧杆菌 FOLFOX6方案化疗 胃肠道症状 不良反应 |
| 收稿时间： | 2020-03-24 |
Study on the role of bifidobacteria in FOLFOX6 chemotherapy for gastric cancer |
| |
| GUO Nan-nan,WU Yi-ting,ZHAO Feng,LIU Yan-wen.Study on the role of bifidobacteria in FOLFOX6 chemotherapy for gastric cancer[J].Journal of Bengbu Medical College,2021,46(11):1510-1512, 1516. |
| |
| Authors: | GUO Nan-nan WU Yi-ting ZHAO Feng LIU Yan-wen |
| |
| Affiliation: | Department of Oncology, Jiangbei Branch of Zhongda Hospital Affiliated to Southeast University, Nanjing Jiangsu 210048, China |
| |
| Abstract: | ObjectiveTo study the role of bifidobacteria in FOLFOX6 chemotherapy for gastric cancer.MethodsEighty patients with gastric cancer were randomly divided into the observation group and control group according to random number table method.The control group were treated with FOLFOX6 chemotherapy, and the observation group were additionally treated with bifidobacteria on the basis of the control group.The total number of lymphocytes(TLC), white blood cell count(WBC), neutrophils (N), intestinal flora, gastrointestinal symptom rating scale(GSRS), clinical efficacy and adverse reaction were compared between two groups.ResultsAfter chemotherapy, the levels of TLC, WBC and N in two groups increased in different degrees compared before chemotherapy(P < 0.05), the levels of TLC and N in control group were lower than those in observation group(P < 0.01), and there was no statistical significance in the level of WBC between two groups(P>0.05).After chemotherapy, the level of lactobacillus in control group was lower than that in observation group(P < 0.01), and the levels of enterobacter, enterococcus and GSRS were higher than those in observation group(P < 0.05 to P < 0.01).There was no statistical significance in total remission rate between two groups(P>0.05).The incidence rate of adverse reactions in observation group was lower than that in control group(P < 0.05).ConclusionsBifidobacterium can improve the body's immunity and gastrointestinal flora distribution and symptoms, and thereby which reduces the adverse reaction of FOLFOX6 chemotherapy. |
| |
| Keywords: | |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《蚌埠医学院学报》浏览原始摘要信息 |
|
点击此处可从《蚌埠医学院学报》下载全文 |
|
